Fate Therapeutics (FATE) Q4 2024 Annual Earnings
FATE·Reported March 5, 2025·Before market open
Fate Therapeutics reported Q4 2024 revenue of $1.9M, beat analyst consensus of $1.6M by $291.3K. Diluted EPS came in at $-0.31, beat the $-0.44 consensus by $0.13.
Revenue
$1.9Mbeat by $291.3K
Consensus: $1.6MDiluted EPS
$-0.31beat by $0.13
Consensus: $-0.44
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Fate Therapeutics's Q4 2024 earnings report.
Fate Therapeutics (FATE) reported Q4 2024 earnings on March 5, 2025 before market open.
Fate Therapeutics reported revenue of $1.9M and diluted EPS of $-0.31 for Q4 2024.
Revenue beat the consensus estimate of $1.6M by $291.3K. EPS beat the consensus estimate of $-0.44 by $0.13.
You can read the 10-K periodic report (0000950170-25-033510) directly on SEC EDGAR. The filing index links above go to sec.gov.